

# Probability of atrial fibrillation after ablation: Using a parametric nonlinear temporal decomposition mixed effects model

Jeevanantham Rajeswaran,<sup>1</sup> Eugene H Blackstone,<sup>1</sup> John Ehrlinger,<sup>1</sup> Liang Li,<sup>2</sup> Hemant Ishwaran<sup>3</sup> and Michael K Parides<sup>4</sup>

Statistical Methods in Medical Research  
2018, Vol. 27(1) 126–141  
© The Author(s) 2016  
Reprints and permissions:  
sagepub.co.uk/journalsPermissions.nav  
DOI: 10.1177/0962280215623583  
journals.sagepub.com/home/smm



## Abstract

Atrial fibrillation is an arrhythmic disorder where the electrical signals of the heart become irregular. The probability of atrial fibrillation (binary response) is often time varying in a structured fashion, as is the influence of associated risk factors. A generalized nonlinear mixed effects model is presented to estimate the time-related probability of atrial fibrillation using a temporal decomposition approach to reveal the pattern of the probability of atrial fibrillation and their determinants. This methodology generalizes to patient-specific analysis of longitudinal binary data with possibly time-varying effects of covariates and with different patient-specific random effects influencing different temporal phases. The motivation and application of this model is illustrated using longitudinally measured atrial fibrillation data obtained through weekly trans-telephonic monitoring from an NIH sponsored clinical trial being conducted by the Cardiothoracic Surgery Clinical Trials Network.

## Keywords

Binary longitudinal response, nonlinear model, mixed effects model, temporal decomposition, multiphase model, time varying coefficient

## 1 Introduction

Arrhythmias are cardiac disorders effecting the regular rhythmic beating of the heart. Atrial fibrillation, one type of arrhythmia, involves different parts of the atria emitting uncoordinated electrical signals. This irregularity causes the heart to beat unevenly and too fast, which also prevents the heart from fully contracting. An estimated 2.5 million Americans are living with atrial fibrillation and estimates indicate as many as 12 million people will have the condition by 2050 (Lloyd-Jones et al.<sup>1</sup>). This makes it the most common *serious* heart rhythm abnormality. Though atrial fibrillation is not life threatening, if left untreated it may lead to serious heart related issues, such as stroke or congestive heart failure. Traditionally, atrial fibrillation has been medically treated with Aspirin or Warfarin. More recently, surgical intervention or catheter ablation has gained widespread acceptance, particularly in patients having concomitant cardiac surgery.

The pathogenesis of atrial fibrillation is incompletely understood and the mechanism(s) of atrial fibrillation vary among affected individuals. The mechanisms are probably more complex than the discrete, well-characterized causes of most other arrhythmias (Gillinov<sup>2</sup>). With this in mind, we focused on assessing the time-varying probability of atrial fibrillation as a binary response, and endeavor to identify patient risk factors whose influence may also be time varying.

<sup>1</sup>Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA

<sup>2</sup>The University of Texas MD Anderson Cancer Center, University of Texas, Houston, TX, USA

<sup>3</sup>Division of Biostatistics, University of Miami, Miami, FL, USA

<sup>4</sup>Mount Sinai Center for Biostatistics, Mount Sinai Hospital, New York, NY, USA

## Corresponding author:

Jeevanantham Rajeswaran, Heart and Vascular Institute, Cleveland Clinic, JJNB-01, 9500 Euclid Avenue, Cleveland 44195, OH, USA.  
Email: rajeswj@ccf.org

## 1.1 Literature review

Longitudinal methods have been widely used in medicine and epidemiology to study the patterns of time varying variables, such as disease progression or trends of health status. In observational studies, one often encounters unbalanced longitudinal data, where each subject can have different number of measurements measured at different time points. In such situations, the correlation among the observations within a subject can be accounted for by using the unobservable random effects. Further, with patient data, it is also an important aim to study patient-specific profiles to improve the quality of patient management. Laird and Ware<sup>3</sup> introduced linear random effects models (mixed effects model) for analyzing continuous response data. However, most of the temporal progression of biological events or biomarkers are nonlinear in nature.<sup>4-6</sup> A thorough overview of the research literature on nonlinear mixed effects modeling, especially with a continuous response, can be found in Davidian and Giltinan<sup>7</sup> and Vonesh and Chichilli.<sup>8</sup> As link functions used for non-normal responses are already nonlinear in nature, most of the literature in nonlinear mixed effect modeling does still involve linear predictor relations. A comprehensive overview of the generalized linear and nonlinear mixed effects modeling for non-normal responses can be found in Molenberghs and Verbeke<sup>9</sup> or Vonesh.<sup>10</sup>

Nonlinear longitudinal models have been widely used to model time-varying clinical data. Most modeling approaches are based on nonparametric methods where, for example, an intercept coefficient is modeled as a function of time using a cubic spline (Guo<sup>11</sup>). “Compartmental” or “multi-phase” models to fit pharmacokinetic data (Pinheiro,<sup>12</sup> Vonesh<sup>13</sup> Molenberghs and Verbeke<sup>9</sup> chap. 20), bi-phase exponential decay model proposed by Wu<sup>14</sup> to fit a temporal trend of virus load in an AIDS study, and a multiphase model proposed by Rajeswaran and Blackstone<sup>15</sup> to fit a temporal trend of longitudinal continuous lung function data are examples of parametric nonlinear models where random effects enter the model nonlinearly. Faes et al.<sup>16</sup> used a nonlinear mixed effects model for binary response data.

Another important aspect of statistical analyses of longitudinal data is to evaluate the effect of covariates where the influence may change with time; coefficients are time-varying. Many time-varying coefficient models use nonparametric approaches.<sup>17-19</sup> Most of the proposed models are for continuous longitudinal responses. Here again, coefficients related to each covariate are modeled as a function of time. However, when the number of covariates in a model is large, as is the case in most observational studies, this approach becomes computationally expensive. In our model, we identify a set of covariates for each time phase, and the influence of these covariate is modulated by the corresponding nonlinear time function. The proposed model for binary longitudinal data is an extension of nonlinear mixed effects model for continuous data proposed by Rajeswaran and Blackstone.<sup>15</sup>

## 1.2 Contribution and outline

In this paper, we present a parametric, nonlinear mixed effects model to fit longitudinal binary data with two major aims in mind: (i) we use multiple, “over-lapping” nonlinear functions of time to explicitly identify the time varying odds/probability of a longitudinal binary response; (ii) we identify patient risk factors whose influence on the binary response may or may not change with time.


In our binary response model, random effects enter the model nonlinearly and can be extended to other response types by changing the link function. The layout of the rest of the paper as follows:

In Section 2, we detail the Cardiothoracic Surgery Clinical Trials Network (CTSN) data that motivated the development of the proposed nonlinear mixed effects temporal decomposition model. In Section 3, we introduce a logistic nonlinear mixed effects model. In Section 4, we discuss the model parameter estimation process. We then demonstrate the application of this model using the longitudinal binary outcome for atrial fibrillation data in Section 5, and in Section 6 we perform a simulation study to assess the model performance. Concluding remarks are given in Section 7.

## 2 The atrial fibrillation study

We investigate data obtained from an NIH sponsored multicenter randomized clinical trial being conducted by the CTSN involving 214 patients enrolled from January 2010 to July 2013. All patients with non-paroxysmal atrial fibrillation undergoing mitral valve procedure were eligible for this trial. The details of the study design are given in Gillinov et al.<sup>20</sup>

The presence atrial fibrillation or normal sinus rhythm was assessed by weekly Trans-telephonic Monitor (TTM) recording. Patients were requested to transmit rhythm data through normal telephone lines every week



**Figure 1.** Frequency of patients with number of post-operative Atrial fibrillation TTM recordings.


for 12 months. Patients who did not transmit at their weekly date were contacted by a research nurse and rhythms were obtained at that time. All the rhythm strips were adjudicated by a research nurse to identify the type of rhythm as atrial fibrillation (AFIB) or normal sinus rhythm (NSR). A total of 6709 rhythm records were available for the 214 patients with 20% of the patients have 50 or more records. The frequency plot in Figure 1 represents the number of patients against the number of TTM recordings for each patient.

Based on the trial protocol, each patient should have a maximum of 52 binary measurements (AFIB: yes/no). However, at the time of the data extraction for analysis, we found that some patients had not completed a full one-year follow-up, and some had transmitted more frequently than every week and some less frequently. We also note that most rhythm data were not obtained at exact weekly intervals. Hence, as typical of observational studies, each patient may have a different number of longitudinal measures at varying points in time. This issue is illustrated in Figure 2, where we show repeated measures of binary TTM response data for 40 patients randomly selected from the full cohort of 214.

We use a crude binned averaging procedure to investigate of the shape of the time varying probability of atrial fibrillation. Figure 3 is constructed by partitioning follow-up times into a number of disjoint groups and taking mean probability of atrial fibrillation. A loess nonparametric method is used to smooth the probability curve. Note that this binned averaging procedure does not take the repeated nature of this data into the account.

Figure 3 indicates that there is a higher probability of AFIB immediately after ablation which peaks around week two. The probability then decreased gradually to about 50% by six months and appears to only slightly decrease thereafter. We interpret this as the odds of atrial fibrillation peaking around two weeks after the procedure and gradually decreased until six months post procedure. The odds stayed relatively constant or increased thereafter at a slower rate if at all. From this, it appears that there may be two phases of odds; an early peaking phase followed by a constant or increasing phase of odds of AFIB.

To investigate the association between baseline covariates and the odds/probability of AFIB, we show the trend of probability of AFIB over time, similar to Figure 3, stratified by selected baseline variables in Figure 4. The figure shows that there is no appreciable difference in the probability of AFIB between age groups split at 75 years. Further, while BMI, diabetes and congestive heart failure (CHF) groups do not have much effect on the early probability, there is a large difference in the later probability of AFIB. The figure then supports the hypothesis that the effect of some risk factors change over time. With Figures 3 and 4 as the motivation, in Section 3, we propose a logistic nonlinear mixed effects model to identify the constituents of temporal decomposition of the nonlinear trend and risk factors whose effects are modulated by the trends.



**Figure 2.** Repeated rhythm (binary) data for 40 randomly selected patients in the descending order of date of surgery (from most recent at the top). Repeated rhythm data are shown horizontally with one row for each patient. Symbols depict normal sinus rhythm (NSR) (circle) and atrial fibrillation (AFIB) (cross) as binary indicators.

### 3 A logistic nonlinear mixed effects model

Let  $Y_{ij}$  be a binary response observed at time  $t_{ij}$  ( $j = 1, \dots, k_i$ ) for  $i$ th subject ( $i = 1, \dots, n$ ), each with an associated set of covariate vector  $\mathbf{X}_i$  of length  $p$ . We define the conditional probability  $\pi_{ij} = E(Y_{ij}|\mathbf{u}_i)$ , where  $\mathbf{u}_i$  is a subject-specific vector of random effects. Suppose the time-varying odds for subject  $i$  can be decomposed into  $\mathcal{L}$  overlapping time phases attenuated by possibly different sets of covariates  $\mathbf{X}_{i\ell}$  with corresponding regression




Figure 3. Probability of atrial fibrillation based on the binned smoothers.




Figure 4. Probability of AFIB based on the binned smoothers stratified by baseline covariates.

coefficients  $\beta_l$  ( $l = 1, \dots, \mathcal{L}$ ), then we write a nonlinear mixed effects model in the odds domain as follows

$$\frac{\pi_{ij}}{1 - \pi_{ij}} = \sum_{l=1}^{\mathcal{L}} \Psi_l(\mathbf{X}_{il}, \beta_l, u_{il}) \Lambda_l(t_{ij}, \Gamma_l) \tag{1}$$

where  $\Lambda_l(t_{ij}, \Gamma_l)$  ( $> 0$ ) is a flexible parametric function depending only on time  $t$  and a shaping parameter vector  $\Gamma_l = (\eta, \gamma, t_{1/2})$ ; and  $\Psi_l(\mathbf{X}_i, \beta_l, u_l)$  is a set of log linear mixed effects models such that

$\Psi_l(\mathbf{X}_{il}, \boldsymbol{\beta}_l, u_{il}) = \exp\{\mathbf{X}_{il}\boldsymbol{\beta}_l + u_{il}\}$ . Here,  $\mathbf{u}_i = (u_{i1}, \dots, u_{i\mathcal{L}})^\top \sim \mathcal{N}(0, \Sigma)$ , a vector of phase-specific random effects for subject  $i$ , and  $\mathbf{Y}_{ij}|u_i \sim \text{Binary}(\pi_{ij})$  are conditionally independent.

Formulation of Model (1) indicates that the  $\mathcal{L}$  multiple overlapping time phases of risk are additive in the odds domain, with each phase shaped by a function of time  $\Lambda_l(t, \boldsymbol{\Gamma}_l)$  and scaled by a multiplicative function of concomitant information  $\Psi_l(\mathbf{X}_{il}, \boldsymbol{\beta}_l, u_{il})$ . This is similar to a formulation of a dynamic multiplicative-additive regression model to analyze survival data, as detailed in Martinussen and Scheike.<sup>21</sup>

Further, by introducing phase specific random effects, we allow the possibility of different variability within different time phases. We rewrite the random effects for patient  $i$  across the phases such that the random effects differ proportionally. Here,  $\mathbf{u}_i = (a_1 u_i, \dots, a_{\mathcal{L}} u_i)^\top$ , where  $a_l$  is the random effect coefficient and  $u_i \sim \mathcal{N}(0, \sigma^2)$ . Hence, the variability of the random effect within each time phase  $l$  is given by  $a_l^2 \sigma^2$ , and for the identifiability purpose, we set  $a_1 = 1$ . Suppose  $a_l = 1$ , for all  $l \in (1, \dots, \mathcal{L})$ , then model (1) reduces to a simple random intercept model, with one common random effect.

Suppose there is a variable (or set of variables), such that a coefficient vector  $\boldsymbol{\beta}_c$  is common to all  $\mathcal{L}$  phases, then model (1) can be further simplified and the proposed logistic nonlinear mixed effect model is given as

$$\text{logit}(\pi_{ij}) = \log\left(\frac{\pi_{ij}}{1 - \pi_{ij}}\right) = \mathbf{X}_{ic}\boldsymbol{\beta}_c + \log\left(\sum_{l=1}^{\mathcal{L}} \Psi_l(\mathbf{X}_{il}, \boldsymbol{\beta}_l, a_l, u_i) \Lambda_l(t_{ij}, \boldsymbol{\Gamma}_l)\right) \quad (2)$$

### 3.1 Time function $\Lambda(t, \boldsymbol{\Gamma})$

We use a generic family of nonlinear functions of time that was originally used to model the cumulative mortality by Blackstone et al.<sup>22</sup> and Hazelrig et al.<sup>23</sup> as the time function  $\Lambda(t, \boldsymbol{\Gamma})$  in our model. The generic family is given by

$$G(t, \boldsymbol{\Gamma}) = \frac{|\eta| - \eta}{2|\eta|} + \frac{\eta}{|\eta|} \left[ 1 + \phi(\gamma) \left( \frac{|\gamma| - \gamma}{2|\gamma|} + \frac{|\eta|t}{\rho} \right)^{-1/\eta} \right]^{-1/\gamma} \quad (3)$$

where  $\gamma > 0$  and/or  $\eta > 0$ ,  $\phi(\gamma) = \gamma$  if  $\gamma > 0$ , and  $\phi(\gamma) = -1$  if  $\gamma < 0$ . Shaping parameter vector  $\boldsymbol{\Gamma} \equiv (\gamma, \eta, t_{1/2})$ , and  $\rho$  is a function of  $t_{1/2}$ ,  $\gamma$ , and  $\eta$ . We define the parameter  $t_{1/2}$  as the time point  $t$  such that  $G(t_{1/2}) = 1/2$ . Natural constraints of  $G$  are that  $G(0, \boldsymbol{\Gamma}) = 0$  and  $G(t, \boldsymbol{\Gamma}) \rightarrow 1$  as  $t \rightarrow \infty$ . When  $\gamma < 0$  and  $\eta < 0$ ,  $G(0) \neq 0$ . This violates the constrain and hence equations (3) does not exist for  $\gamma < 0$  and  $\eta < 0$ . Hence, the formulation (3) simplifies into three cases when  $\gamma > 0$  and  $\eta > 0$ ;  $\gamma > 0$  and  $\eta < 0$ ;  $\gamma < 0$  and  $\eta > 0$  (see supplementary materials available at <http://smm.sagepub.com>).

The motivation to use this type of time function in our modeling is that time-varying odds of the AFIB in Figure 3 has a similar shape as a time-varying hazard of death after a cardiac surgery. Further, this generic family can almost handle any shapes. The function  $G(t, \boldsymbol{\Gamma})$  or any of its transformations can be used as  $\Lambda_l(t, \boldsymbol{\Gamma}_l)$ . In our data analysis experience, the most frequently used early and late phase functions are  $g(t, \boldsymbol{\Gamma}) = \frac{\partial G(t, \boldsymbol{\Gamma})}{\partial t}$  and  $h(t, \boldsymbol{\Gamma}) = \frac{g(t, \boldsymbol{\Gamma})}{1 - G(t, \boldsymbol{\Gamma})}$ , respectively. Note that in ‘survival’ terminology, suppose  $G(t, \boldsymbol{\Gamma})$  is cumulative hazard,  $g(t, \boldsymbol{\Gamma})$  is the hazard. On the other hand, if  $G(t, \boldsymbol{\Gamma})$  is cumulative distribution function,  $h(t, \boldsymbol{\Gamma})$  is the hazard function. In our data analysis experience, most of the nonlinear trends can be modeled using only two phases and very rarely we use three phases. Detailed description of equations, limiting behavior and the shapes of some possible functions are given in the supplementary material.

Development of the generic equation (3) took place over more than a decade in the 1970s, and represents a differential equation that Blackstone and colleagues<sup>23,24</sup> formed from apparently disparate dynamic models of biochemical reaction rates, physical laws of thermodynamics, allometric growth, ecologic predator-prey phenomena, and population growth. They also established the relationship to certain statistical models. Special case models are found by setting exponents to  $\pm 1$  and  $0/\infty$  that lead to linear and various non-linear models, all nested by dint of the common generic differential equation.

Thus, the models not only simplify (usually substantially), but have robust statistical properties useful in nonlinear iterative unbounded optimization. The idea of multiple phases arose out of the Makeham–Gompertz law of mortality (which has an age-dependent and an age independent component), from 1860. The three-phase model for the time to event response, proposed by Blackstone et al.,<sup>22</sup> permits multiple streams of concomitant information (including the same variables) to be estimated simultaneously. In the present paper, we have extended the approach to accommodate longitudinal response with the number of components on phases is unlimited. This

permits us to characterize the temporal pattern and then independently modulate the pattern by phase-specific risk factors as well as modulating the entire course.

Further, the present formulation for longitudinal data differs from that was developed for survival (Blacksone et al.<sup>3</sup>) in that we have used a single flexible component (equation (3)) for all phases, because by setting the exponents to various values, the equation reduces to a constant, to a Weibull-type increasing, to a decreasing or peaking function or combination of these. Further, these are the shapes that we frequently observe in a temporal trend of biomarkers or biologic mechanisms, such as AF, after cardiac surgery.<sup>25–29</sup>

## 4 Estimation

Shaping parameters and concomitant information coefficients are estimated by the method of marginal maximum likelihood (Diggle et al.<sup>30</sup>: 172). Let  $\boldsymbol{\beta} = (\boldsymbol{\beta}_c, \boldsymbol{\beta}_1, \dots, \boldsymbol{\beta}_L)$ ,  $\mathbf{a} = (a_1, \dots, a_L)$  and  $\boldsymbol{\Gamma} = (\boldsymbol{\Gamma}_1, \dots, \boldsymbol{\Gamma}_L)$ , then the likelihood function for the unknown parameter  $\delta = (\boldsymbol{\beta}, \mathbf{a}, \boldsymbol{\Gamma}, \sigma^2)$  is

$$\begin{aligned} L(\delta|\mathbf{y}_i) &= \prod_{i=1}^n \int_{-\infty}^{\infty} f(\mathbf{y}_i|u_i) f(u_i; \sigma^2) du_i \\ &= \prod_{i=1}^n \int_{-\infty}^{\infty} \prod_{j=1}^{k_i} \pi_{ij}^{y_{ij}} (1 - \pi_{ij})^{1-y_{ij}} \phi(u_i|0, \sigma^2) du_i \end{aligned} \quad (4)$$

where  $f(\mathbf{y}_i|u_i)$  is the conditional density of the binary longitudinal response, and  $f(u_i; \sigma^2)$  is the density of the random effect,  $u_i$ , assumed to be a normal distribution with mean 0 and variance  $\sigma^2$ ,  $\phi(\cdot|0, \sigma^2)$ . Note that equation (4) is merely the marginal distribution  $\mathbf{Y}$  obtained by integrating the joint distribution of  $\mathbf{Y}$  and  $U$  with respect to  $U$ . The maximum likelihood estimates are obtained using the marginal likelihood function. For the Logistic mixed effects model (2), since the random effects is a nonlinear function of the conditional mean, there is no closed form solution for equation (4). In general, except for some special cases, equation (4) does not have closed-form solution. Hence, it involves numerical integration. Note that, by assuming distribution of the random effect  $U$  a Beta distribution, Kleinman<sup>31</sup> obtained a closed form solution, a beta-binomial distribution. McCulloch<sup>32</sup> provides some details on using an extension of the EM algorithm for parameter estimation in generalized linear mixed effects models. Laplace approximation is another popular method for parameter estimation in nonlinear mixed effects models. However, Joe<sup>33</sup> cautioned in using this approach in non-normal scenario. For generalized linear mixed effects model, another estimation approach is to use Taylor series expansion around regression coefficient and/or around random effects (see for example, Breslow and Clayton<sup>34</sup>). In general, there are “exact” and “approximate” methods available for parameter estimation. The “approximate methods” such as Taylor series or Laplace approximation avoid integration. However, for non-normal responses, these methods may lead to biased estimation (see for example, Wu<sup>35</sup>: chap. 2). Higher-order approximations are proposed to improve the estimation (see for example, Lee et al.<sup>36</sup>). We use Gauss-Hermite quadrature, which is an “exact” method, for integration of equation (4) with respect to the random effect to determine the marginal likelihood function. However, it should be noted that this method is computationally expensive, and at times unfeasible when the dimension of random effect is large. In our model, however, we have kept the dimension of the random effect at 1. We implemented the parameter estimation using PROC NL MIXED (SAS<sup>®</sup>, Inc., Cary, NC). Note that the implementation of this SAS procedure is mainly based on Pinheiro and Bates.<sup>12</sup>


Note that, by using equation (2), we can estimate the conditional probability  $E(\widehat{Y}_{ij}|u_i) = \widehat{\pi}_{ij}(u_i)$ . If one is also interested in estimating the marginal probability  $E(\widehat{Y}_j)$  from this model, one can integrate the conditional probability over the distribution of random intercept  $u_i$  (Fitzmaurice et al.<sup>37</sup>) to obtain the marginal estimates. Then

$$E(\widehat{Y}_j) = E_u(E(\widehat{Y}_{ij}|u_i)) = \int_{-\infty}^{\infty} \widehat{\pi}_{ij}(u_i) f(u_i; \sigma^2) du_i$$

where  $f(u_i; \sigma^2)$  is the density function of  $u_i$ . Note that, one can approximate the  $E(\widehat{Y}_j) \approx \frac{1}{n} \sum_{i=1}^n E(\widehat{Y}_{ij}|u_i)$ .

## 5 Data analysis

In this section, we first focus on the problem of explicitly modeling the nonlinear time-varying trend of odds/probability of AFIB. We then focus on the factors associated with odds/probability of AFIB after the ablation procedure. In the multivariable analysis, we consider the following ten covariates: age at the time of the procedure;



**Figure 5.** The exact decomposition of temporal trend in odds domain for a typical patient ( $u_i = 0$ ).

gender; race; histories of congestive heart failure, cardiovascular disease, hypertension, diabetes; creatinine, diastolic and systolic blood pressure, and international normalized ratio.

### 5.1 Temporal decomposition and trend

In this section, we consider model (2) without covariates and the focus is on the estimation of shaping parameters  $\Gamma$ s. Without covariates, model (2) can be written as

$$\text{logit}(\pi_{ij}) = \log \left( \sum_{l=1}^{\mathcal{L}} \Psi_l(\beta_{0l}, a_l, u_i) \Lambda_l(t_{ij}, \Gamma_l) \right) \quad (5)$$

where  $\beta_{0l}$  is phase specific intercept (fixed effect).

Temporal trend analysis yields a bi-phase model: An early peaking and a late increasing phase. Figure 5 shows the temporal decomposition of time varying odds for a “typical patient” or “average patient”, decomposition when  $u_i = 0$ . Although the late increasing phase is very small for the “typical patient”, it can increase for some patients through the estimates of  $u_i$ . The estimates and the standard error of the shaping parameters and standard deviation of distribution of  $u_i$  are given in Table 1.

It can be noted here that the estimated standard deviation of the random effect in the early peaking phase is 3.0 and that of late increasing phase is 12.5. This suggests that there is a larger variability in subject-specific profiles in late time phase than in the early time phase. Based on the estimates in Table 1, the estimated multiphase temporal trend equation for odds of AFIB can be simplified as in equation (6)

$$\frac{\hat{\pi}_{ij}}{1 - \hat{\pi}_{ij}} = \exp(2.6 + u_i) \frac{0.73}{t_{ij}^2 \exp(0.73/t_{ij})} + \exp(4.2u_i) \frac{0.22}{(0.16t_{ij})^{2.3}} \quad (6)$$


*Remark:* We have used  $\Lambda_1(t, \Gamma_1) = g(t, \Gamma)$  under the limiting Case 1 (see supplementary material) as the early phase equation with shaping parameters  $\eta$  and  $\gamma$  are fixed at 1 and 0, respectively. We then used  $\Lambda_2(t, \Gamma_2) = h(t, \Gamma)$  under the limiting Case 1 as the late phase equation, with  $\eta$  is a positive value and  $\gamma$  is fixed at 0. To get mathematically tractable stable functions, when the estimate of  $\eta$  or  $\gamma$  is almost 0, we use one of the limiting cases and when the estimate of  $\eta$  and/or  $\gamma$  is almost 1 (not significantly different from 1), we simplify the  $G(t, \Gamma)$  by fixing  $\eta$  and/or  $\gamma$  at 1. Further, since in the transformed function  $h(t, \Gamma)$ ,  $t_{1/2}$  acts as the scalar, to avoid redundancy in the parametrization of covariate information in  $\Psi(\cdot)$ , whenever one uses  $h(t, \Gamma)$  as the time function we take the  $\beta_0$



**Table 1.** Estimates of shaping parameter of the temporal trend of odds of AFIB.

Parameter	Estimate ± SE	P
<b>Early peaking phase</b>		
$\hat{\beta}_{01}$	2.6 ± 0.23	<0.0001
$\hat{\eta}$	1	–
$\hat{\gamma}$	0	–
$\hat{t}_{1/2}$	1.05	–
<b>Late increasing phase</b>		
$\hat{\beta}_{02}$	0	–
$\hat{\eta}$	0.76 ± 0.33	0.02
$\hat{\gamma}$	0	–
$\hat{t}_{1/2}$	7.9	–
<b>Random effect coefficients</b>		
$a_1$	1	–
$\hat{a}_2$	4.2 ± 0.69	<0.0001
$\widehat{var}(u) = \hat{\sigma}^2$	8.9 ± 1.7	<0.0001


Note: In the early phase,  $\gamma=0$  means  $\Lambda(t, \Gamma) = g(t, \Gamma)$  when  $\eta > 0$  and  $\gamma \rightarrow 0^+$  and in the late phase  $\gamma=0$  means  $\Lambda(t, \Gamma) = h(t, \Gamma)$  when  $\eta > 0$  and  $\gamma \rightarrow 0^+$  (see supplementary material further details). Further note that  $\hat{\beta}_{02}$  is set to 0 when using  $h(t, \Gamma)$  as  $\Lambda(t, \Gamma)$ .



**Figure 6.** Patient-specific probability profiles and the average of the profiles.

as 0. Hence, phase identification and parameter estimation are determined by the data in an ad hoc manner. The process is briefly as follows: based on the overall binned smoother trend (Figure 3), we started with two phases: an early phase using  $g(t, \Gamma)$  with a smaller value (1 month) for  $t_{1/2}$ ; and a late phase using  $h(t, \Gamma)$  with a larger value (six months) for  $t_{1/2}$  as starting values. For  $\eta$  and  $\gamma$ , we have tried three possible combinations (1, -1), (1, -1) and (1, 1) as starting values for both phases and observed which combination gives a stable estimation with larger likelihood. For both phases, it turns out to be that the estimate of  $\gamma$  is almost 0. For  $\eta$ , early phase estimate is almost 1 (not significantly different from 1) and for the late phase, it is a positive value different from 0 or 1.

Figure 6 shows the patient-specific profiles and the average of the profiles and Figure 7 depicts the average of the profile superimposed on the binned smoothers. It can be noted from Figure 2 that some patients do not have data as follow-up gets longer. Therefore, not all the patients contribute to the binned averages as follow-up gets



**Figure 7.** Average of the patient-specific profiles and binned averages. Binned averages are the average of available data at various follow-up time intervals without taking into the consideration of the possibility that some of these observations are correlated, provided here as a crude verification of model fit.

longer. However, average curve is obtained by averaging all patient-specific curves at each time point. This may explain the deviation between the estimated curve and the binned averages in Figure 7. Although the probability based on the average of the patient-specific profiles increased from about 0.45 to about 0.75 within a month after the ablation and gradually decreased to about 0.45 by month 6 and remained constant thereafter, there is a large variability in the patient-specific probability profiles of AFIB after ablation. By one year, around 45% of the patients have the probability less than 5%, and 30% have the probability greater than 95%.

*An alternative model:* Using Akaike Information Criteria (AICc), we have compared model (5) with the following simpler alternative model

$$\text{logit}(\pi_{ij}) = \log \left( \sum_{l=1}^{\mathcal{L}} \Psi_l(\beta_{0l}) \Lambda_l(t_{ij}, \Gamma_l) \right) + v_i \quad (7)$$

where  $V \sim \mathcal{N}(0, \tau^2)$ . Here, instead of patient-specific random effects for each phase, we simplify the model with patient-specific random intercepts.


Based on the AICc values (Main Model (5): AICc = 3300.8; Alternative Model (7): AICc = 3395.7), model (5) which has subject-specific random effects for each phase, is better than alternate model, a random intercept model (7), which has one common random effect.

## 5.2 Factors associated with temporal change odds of AFIB

We now illustrate the multivariable analysis to identify phase-specific baseline covariates that are associated with AFIB after ablation using some selected variables. We have considered the following variables in the analyses: Demography (age, gender, race, body mass index (BMI)), cardiac comorbidity (congestive heart failure – (CHF), cardio vascular disease (CVD), hypertension (HTN)), non-cardiac comorbidity (diabetes, serum creatinine, diastolic and systolic blood pressure, international normalized ratio (INR)). Our objective here is to identify variables (1) that are associated with the early outcomes; (2) that are associated with the late outcomes; (3) that influence the outcome regardless of the time phase. Because of limited built-in capability of performing variable selection using PROC NLMIXED, we have used an ad hoc selection strategy as follows: we first force in a variable in each phase and noted its significance and the magnitude of the regression coefficients. If the magnitudes are at least approximately equal and are significant in at least one phase, we move this variable as a

**Table 2.** Patient-specific risk factors associated with AFIB.

Parameter	Estimate ± SE	P
<b>Overall</b>		
None	–	–
<b>Early peaking phase</b>		
BMI	1.6 ± 0.67	0.02
<b>Late increasing phase</b>		
BMI	–1.5 ± 0.55	0.008
Diabetes	9.6 ± 2.4	<0.0001
Congestive Heart Failure	6.0 ± 1.9	0.002



**Figure 8.** Estimated probability of post-op AFIB for a “typical patient” ( $u_i = 0$ ) stratified by different baseline covariates.


common variable. If it is, on the other hand, significant in both phases with different magnitudes, we will keep this variable in both phases. Finally, if the variable is significant only in one phase, we keep that variable only in that phase. We continue this “forward-selection like” process until we consider all the variables in the model.

Table 2 shows the patient-specific estimates of regression coefficients of the selected covariate that are significantly associated with post ablation probability of AFIB.

Figure 8 depicts the estimated probability stratified by BMI, diabetes and congestive heart failure variables for a “typical patient”. Based on the limited variable selection and analysis, among the patient demographics, while larger body mass index is associated with early elevated risk of having AFIB, its direction of effect appears to change in the late odds of AFIB (top row – Figure 8). Notably, neither age nor gender has any impact on the likelihood AFIB. Having history of congestive heart failure and diabetes also appear to be associated with late elevated odds of having AFIB. Particularly, diabetes appears have a larger impact on the likelihood of late AFIB (bottom row – Figure 8).

## 6 A simulation study

We assess the performance of model (2) using a focused simulation study. The major objective of this study is to assess performance of the shaping parameters and the regression coefficient estimators. The simulation study does



**Figure 9.** True shapes of the phases for temporal trend in the simulated model for a typical patient ( $u_i = 0$ ). Dash lines depict the shapes of the early and the late phases and the solid line depicts total odds.

not focus on model building; instead, given a model, we would like to assess how well the parameters are estimated.

We generated a binary longitudinal response for 250 subjects. Mimicking the data described in Section 2 (Figure 2), we assumed that the first 150 patients have complete follow-up data and the remaining 100 patients have partial follow-up based on the staggering study entry (assumed linear). For the first 150 patients, we generated the data at the following 18 time points over a 12-month period: one-day, two-day, three-day, five-day, one-week, two-week, and 12-monthly time points at month 1 through month 12. For the remaining 100 patients, assuming they have a minimum of three months of follow-up, we generated data at the first nine time points in the first three months and then depend on the study entry, we generated the remaining data. We have generated 1000 simulated datasets with sample size of 250.

For the temporal trend, we assume a bi-phase model with  $\Lambda_1(t, \Gamma) = g(t, \Gamma)$ , with  $\Gamma = (\eta = 1, \gamma = 0, t_{1/2} = 1)$  as the early phase (limiting Case 1 in supplementary material) and  $\Lambda_2(t, \Gamma) = h(t, \Gamma)$ , with  $\Gamma = (\eta = -0.5, \gamma = 0, t_{1/2} = 5)$  as the late phase (limiting Case 3 in supplementary material). Equation  $\Lambda_1(t, \Gamma)$  with the selected values for the shaping parameters shows an early peaking function and  $\Lambda_2(t, \Gamma)$  with the selected values gives a late increasing function (Figure 9). For simplicity, we generate three covariates as follows  $V_1 \sim \text{Binary}(0.25)$ ,  $V_2 \sim \mathcal{N}(\text{mean} = 0, \text{sd} = 0.5)$ , and  $V_3 \sim \text{Binary}(0.4)$ .  $V_1$  is an early phase factor that positively associated with the response;  $V_3$  is a late phase factor that positively associated with the response;  $V_2$  positively associated with the response in both phases with higher influence in early than in the late. The random effect  $u_i \sim \mathcal{N}(\text{mean} = 0, \text{sd} = 3)$  with coefficients  $(a_1 = 1, a_2 = 2)$  with  $a_1$  is fixed at 1 and  $a_2$  is estimated.

## 6.1 Simulation results

We now assess the performance of the logistic multiphase nonlinear mixed effects model based on simulated data using the following summary measures: Average Bias:  $\%Bias = 100 \times (\theta - \tilde{\theta})/|\theta|$ , where  $B$  is the number of simulated datasets,  $\theta$  is the true value,  $\hat{\theta}_i$  is the estimate from the  $i$ th simulated dataset and  $\tilde{\theta} = 1/B \sum_{i=1}^B \hat{\theta}_i$ ; average within standard error,  $AvgSE = \sum_{i=1}^B SE(\hat{\theta}_i)/B$ , where  $SE(\hat{\theta}_i)$  is the estimated standard error of  $\hat{\theta}_i$ ; empirical standard error,  $EmpSE = \sqrt{[1/(B-1)] \sum_{i=1}^B (\hat{\theta}_i - \tilde{\theta})^2}$ ; 95% coverage probability,  $CP$ .

The summary measures of the shaping and regression coefficients of the covariates based on the 1000 simulated data with sample size 250 are given in Table 3.

**Table 3.** Summary measures of the parameter estimates based on the 1000 simulated data with sample size 250.

Parameter	True value	% Bias	AvgSE	EmpSE	CP
<b>Early peaking phase</b>					
$V_0$	-1	2.96	0.4244	0.04406	0.934
$V_1$	1	-1.55	0.3382	0.3448	0.956
$V_2$	1	-0.892	0.4992	0.4965	0.953
<i>Shaping parameters</i>					
$\eta$	1	1.74	0.1581	0.1698	0.924
$t_{1/2}$	1	-5.09	0.3926	0.4403	0.874
<b>Late increasing phase</b>					
$t_{1/2}$	5	-1.71	1.264	1.355	0.927
$V_2$	0.5	6.22	0.8261	0.8224	0.950
$V_3$	0.5	3.77	0.5552	0.5837	0.940
<i>Shaping parameters</i>					
$\eta$	-0.5	-0.356	0.0199	0.0197	0.946
<b>Random effect</b>					
$Var(U) = \sigma^2$	9	-1.48	2.472	2.581	0.928
Coefficient - $a_2$	2	0.528	0.2872	0.2990	0.921

**Table 4.** Summary measures of the parameter estimates based on the 1000 simulated data with varying sample size.

Parameter	True value	Sample size											
		$n = 500$				$n = 250$				$n = 100$			
		Bias (%)	AvgSE	EmpSE	CP	Bias (%)	AvgSE	EmpSE	CP	Bias (%)	AvgSE	EmpSE	CP
<b>Early peaking phase</b>													
$V_0$	-1	-0.768	0.2921	0.2855	0.954	2.96	0.4244	0.4406	0.934	11.9	0.6961	0.7532	0.928
$V_1$	1	-0.085	0.2313	0.2358	0.942	-1.55	0.3382	0.3448	0.956	-1.36	0.5738	0.5902	0.961
$V_2$	1	0.793	0.3444	0.3450	0.944	-0.892	0.4992	0.4965	0.953	-2.45	0.8406	0.8616	0.954
<i>Shaping parameters</i>													
$\eta$	1	0.984	0.1102	0.1085	0.943	1.74	0.1581	0.1698	0.924	4.40	0.2433	0.2845	0.848
$t_{1/2}$	1	-1.39	0.2491	0.2610	0.932	-5.09	0.3926	0.4403	0.874	-18.8	0.8868	1.111	0.790
<b>Late increasing phase</b>													
$t_{1/2}$	5	1.07	0.8576	0.8578	0.922	-1.71	1.264	1.355	0.927	-16.6	2.439	3.191	0.941
$V_2$	0.5	9.17	0.5808	0.5730	0.952	6.22	0.8261	0.8224	0.950	10.1	1.348	1.467	0.934
$V_3$	0.5	0.691	0.3866	0.3918	0.946	3.77	0.5552	0.5837	0.940	-12.3	0.9148	0.9376	0.954
<i>Shaping parameters</i>													
$\eta$	-0.5	0.183	0.0140	0.0143	0.942	-0.356	0.0199	0.0197	0.946	0.272	0.0311	0.0332	0.933
<b>Random effect</b>													
$Var(U) = \sigma^2$	9	1.81	1.679	1.658	0.946	-1.48	2.472	2.581	0.928	-8.55	4.289	4.689	0.925
Coefficient - $a_2$	2	0.265	0.1993	0.2003	0.933	0.528	0.2872	0.2990	0.921	-1.80	0.4972	0.5322	0.938

All the estimated parameters, except the  $t_{1/2}$  in the early phase and  $V_2$  in the late phase, have smaller bias. However, other summary measures of  $V_2$  appear to be closer to the expected values. This suggests, in general, our logistics nonlinear mixed effect model performs as expected in estimating the parameters.

### 6.2 Varying sample size

In this simulation scenario, we simulate three sample sizes:  $n = 500$  – a large sample size;  $n = 250$  – a moderate sample size; and  $n = 100$  – a small sample size, and compare the influence of varying sample sizes on the performance of parameter estimation.

Table 4 shows the summary estimates for three different sample sizes. In general, as sample size decreases, there appears to be some increase in bias and standard error of the parameter estimates. This is apparent, particularly

**Table 5.** Summary measures of the parameter estimates based on the 1000 simulated data with different random effect coefficients.

Parameter	True value	True Random Effect coefficient for phase 2							
		$a_2 = 2$				$a_2 = 1$			
		Bias (%)	AvgSE	EmpSE	CP	Bias (%)	AvgSE	EmpSE	CP
<b>Early peaking phase</b>									
$V_0$	-1	54.8	0.5421	0.6030	0.806	1.93	0.3351	0.3384	0.946
$V_1$	1	-37.4	0.4369	0.5110	0.83	-1.60	0.3119	0.3141	0.949
$V_2$	1	-46.1	0.7519	0.7603	0.908	-0.871	0.4581	0.4544	0.952
<i>Shaping parameters</i>									
$\eta$	1	10.0	0.1552	0.1984	0.785	0.467	0.1034	0.1105	0.924
$t_{1/2}$	1	-3.18	0.4524	1.606	0.780	-2.70	0.2535	0.2772	0.907
<b>Late increasing phase</b>									
$t_{1/2}$	5	17.3	0.8516	0.9273	0.704	-1.56	0.6373	0.6414	0.946
$V_2$	0.5	10.0	0.6769	0.6826	0.947	2.33	0.4299	0.4264	0.954
$V_3$	0.5	27.8	0.3876	0.4700	0.881	-0.458	0.2708	0.2695	0.954
<i>Shaping parameters</i>									
$\eta$	-0.5	8.52	0.0172	0.0169	0.288	-0.548	0.0189	0.0190	0.959
<b>Random effect</b>									
$Var(U) = \sigma^2$	9	-160	3.482	3.301	0.000	0.618	1.235	1.261	0.929

when the sample size is 100. One reason may be that our model has larger number of parameters (12, in this simulated model) to be estimated. As a result, there may be decrease in efficiency with decreased sample size. To have a better performance in the parameter estimation, we may need at least a moderate sample size.

### 6.3 Influence of random effect coefficient

In this simulation scenario, we illustrate the influence of the random effect coefficient. We know that if the random effect coefficients are all equal to 1, the model can be simplified into a random intercept model. However, when the true coefficient is different from 1, the performance of the model under the assumption that the coefficients are all equal to 1 is not clear. We simulated data based on a bi-phase model as described at the beginning of this section with sample size equal to 250, but under two scenarios of random effect coefficient: (i).  $a_2 = 2$  and (ii).  $a_2 = 1$ . We then assess the model performance under the assumption of  $a_2 = 1$ .

Table 5 shows the summary estimates based on the assumption of random intercept model ( $a_2 = 1$ ), for data simulated under two different true values of  $a_2$ . As expected, when the true value of the coefficient is 1, the random intercept model performs very well. However, when the true value of the coefficient is 2, the random intercept model perform very poorly as this is equivalent to misspecifying the correlation structure.

## 7 Conclusion

In this article, we have proposed and demonstrated a nonlinear multiphase mixed effects model to analyze longitudinal binary data. Our model is different from classical generalized linear mixed effects model in that, the time varying odds of an event can be decomposed into multiple overlapping linear or nonlinear time phases, thus explicitly identifying the linear or nonlinear time-varying trend. Further, each phase can have its own stream of concomitant information and patient specific random effect. In medical science, these two features are important components in patient management after a procedure. Knowledge of the both patient-specific/overall time-varying temporal trend of an event and of the phase-specific (time specific) factors that influence the early and late events would enable a physician to tailor the post-procedure patient management according to patient risk factors. For example, in our data analysis, we have shown that higher body mass index is an early risk factor and diabetes is a late risk factor. Based on this information, a physician can closely monitor an obese patient right after the procedure and for diabetes patients, set up more follow-up visits, say, after three months. Further, the

multiphase model we proposed is similar to time-varying coefficient models. However, when analyzing this type of cardiac data, the main advantage of the multiphase model over the time varying coefficient models is that, with time varying coefficient models, coefficient for each covariate in the model is a smooth function of time and this may pose computational difficulties when there are many covariates. On the other hand, the multiphase model still works with large number of covariates, but with more restrictive model assumption that the covariates within a phase have similar shape of time varying effect. However, these assumptions are likely to be satisfied for cardiac data.<sup>25–29</sup>

We have demonstrated the application of this model using a readily available software and this feature is another advantage of our model. Further, by reparameterization of patient specific random effects in each phase, we have reduced the dimension of random effects to one, regardless of number of phases. This has greatly reduced computational difficulties arising from numerical integration being used in parameter estimation.

We have used the cumulative mortality function used by Hazelrig et al.<sup>23</sup> as the generic time function for our analysis. This is a very flexible family of functions that can handle almost any shapes. In our data analysis experience in cardiac surgery, models with two phases are the most frequent, very rarely, a three-phase model. We have never encountered a model with four phases. Hence, although the process of variable selection is ad hoc, having to deal with only two (or at most three) phases makes the data analysis plausible and tractable. Variable selection in longitudinal models is an active area of research.

The model (2) can be easily extended to accommodate other type of longitudinal data – continuous, ordinal, and nominal – by changing the link functions related to the corresponding conditional distributions, and, in the case of ordinal data, introducing cut-off parameters. These extensions are currently under active research in our group. Further, another active area of research currently under consideration is the extension of model (2) to handle multivariate longitudinal data of same type (for example, all continuous) or different types (continuous and binary).

## Acknowledgements

The authors would like to thank the reviewers for their helpful and constructive comments.

## Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was partially supported by a grant from National Institutes of Health – NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, Grant Number: 1R01HL103552.

## Supplement material

Supplementary material is available for this article online.

## References

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics–2010 update. A report from the American Heart Association. *Circulation* 2010; **121**: e1–e170.
2. Gillinov AM. Choice of surgical lesion set: Answers from the data. *Ann Thoracic Surgery* 2007; **84**: 1786–1792.
3. Laird NM and Ware JH. Random-effects models for longitudinal data. *Biometrics* 1982; **38**: 963–974.
4. Muller P and Rosner GL. A Bayesian population model with hierarchical mixture prior applied to blood count data. *J Am Statist Assoc* 1997; **92**: 1279–1292.
5. Mikulich SK, Zerbe GO, Jones RH, et al. Comparing Linear and Nonlinear mixed model approaches to Cosinor analysis. *Statist Med* 2003; **22**: 3195–3211.
6. Wu H and Ding A. Population HIV-1 dynamics in vivo: Applicable models and inferential tools for virological data from AIDS clinical trials. *Biometrics* 1999; **55**: 410–418.
7. Davidian M and Giltinan DM. *Nonlinear models for repeated measurement data*. New York: Chapman and Hall, 1995.

8. Vonesh EF and Chinchilli VG. *Linear and nonlinear models for the analysis of repeated measurements*. London: Chapman and Hall, 1997.
9. Molenberghs G and Verbeke G. *Models for discrete longitudinal data*. New York: Springer, 2005.
10. Vonesh EF. *Generalized linear and nonlinear models for correlated data: Theory and applications using SAS*. Cary, NC: SAS Institute Inc, 2012.
11. Guo W. Functional data analysis in longitudinal setting using smoothing splines. *Statis Meth Med Res* 2004; **13**: 49–62.
12. Pinheiro JC and Bates DM. Approximations to the log-likelihood function in the non-linear mixed-effects model. *J Computat Graphic Stat* 1995; **4**: 12–35.
13. Vonesh EH. Non-linear models for the analysis of longitudinal data. *Stat Med* 1992; **11**: 1929–1954.
14. Wu L. A joint model for nonlinear mixed-effects models with censoring and covariates measured with error, with application to AIDS studies. *J Am Stat Assoc* 2002; **97**: 955–964.
15. Rajeswaran J and Blackstone EH. A multiphase non-linear mixed effects model: An application to Spirometry after lung transplantation. *Stat Meth Med Res* 2017; **26**: 21–42.
16. Faes C, Aerts M, Geys H, et al. Bayesian testing for trend in a power model for clustered binary data. *Environ Ecol Stat* 2004; **11**: 305–322.
17. Wu CO and Yu KF. Nonparametric varying-coefficient models for the analyses of longitudinal data. *Int Stat Rev* 2000; **3**: 373–393.
18. Wu H and Zhang JT. *Nonparametric regression methods for longitudinal data analysis: Mixed-effects modeling approaches*. New York: John Wiley & Sons Inc, 2006.
19. Senturk D and Muller HG. Generalized varying coefficient models for longitudinal data. *Biometrika* 2008; **95**: 653–666.
20. Gillinov AM, Argenziano M, Blackstone EH, et al. Designing comparative effectiveness trials of surgical ablation for atrial fibrillation: Experience of the Cardiothoracic Surgical Trials Network. *J Thorac Cardiovasc Surg* 2011; **142**: 257–264.
21. Martinussen T and Scheike TH. *Dynamic regression models for survival data*. New York: Springer, 2005.
22. Blackstone EH, Naftel DC and Turner ME Jr. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. *J Am Stat Assoc* 1986; **81**: 615–624.
23. Hazelrig JB, Turner ME Jr. and Blackstone EH. Parametric survival analysis combining longitudinal and cross-sectional censored and interval-censored data with concomitant information. *Biometrics* 1982; **38**: 1–15.
24. Turner ME, Hazelrig JB and Blackstone EH. Bounded survival. *Math Biosci* 1982; **59**: 33–46.
25. Banga A, Gildea T, Rajeswaran J, et al. The natural history of lung function after lung transplantation for a1-antitrypsin deficiency. *Am J Respiratory Crit Care Med* 2014; **190**: 274–281.
26. Beach JM, Mihaljevic T, Rajeswaran J, et al. Ventricular hypertrophy and left atrial dilatation persist and are associated with reduced survival after valve replacement for aortic stenosis. *J Thorac Cardiovasc Surg* 2014; **147**: 362–369.
27. Mason DP, Rajeswaran J, Li L, et al. Effect of changes in postoperative spirometry on survival after lung transplantation. *J Thorac Cardiovasc Surg* 2012; **144**: 197–203.
28. Mason DP, Rajeswaran J, Murthy SC, et al. Spirometry after transplantation: How much better are two lungs than one? *Ann Thorac Surg* 2008; **85**: 1193–1201.
29. Gillinov AM, Bhavani S, Blackstone EH, et al. Surgery for permanent atrial fibrillation: Impact of patient factors and lesion set. *Ann Thoracic Surg* 2006; **82**: 502–514.
30. Diggle JD, Heagerty P, Liang K-Y, et al. *Analysis of longitudinal data*, (2nd version). New York: Oxford, 2002.
31. Kleinman J. Proportions with extraneous variance: Single and independent samples. *J Am Stat Assoc* 1973; **68**: 46–54.
32. McCulloch CE. Maximum likelihood algorithm for generalized linear mixed models. *J Am Stat Assoc* 1997; **92**: 162–170.
33. Joe H. Accuracy of Laplace approximation for discrete response mixed models. *Computat Data Analysis* 2008; **52**: 5066–5074.
34. Breslow NE and Clayton DG. Approximate inference in generalized linear mixed models. *J Am Stat Assoc* 1993; **88**: 9–25.
35. Wu L. *Mixed effects models for complex data*. New York: Chapman and Hall, 2010.
36. Lee H, Nelder JA and Pawitan Y. *Generalized linear models with random effects: Unified analysis via H-likelihood*. New York: Chapman and Hall, 2006.
37. Fitzmaurice GM, Laird NM and Ware SL. *Applied longitudinal analysis*. New Jersey: John Wiley & Sons, 2002.